<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02138786</url>
  </required_header>
  <id_info>
    <org_study_id>KCP-330-010</org_study_id>
    <nct_id>NCT02138786</nct_id>
  </id_info>
  <brief_title>Selinexor in Initial or Relapsed/Refractory Richter's Transformation</brief_title>
  <acronym>SIRRT</acronym>
  <official_title>A Phase 2 Study of the Safety and Anti-tumor Activity of the Oral Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Initial or Refractory and/or Relapsed Richter's Transformation (RT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karyopharm Therapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karyopharm Therapeutics Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multi-center, Phase 2, single arm, open-label study of oral selinexor monotherapy
      in patients in patients with Richter's transformation, arising in the setting of prior CLL,
      after at least one chemo-immunotherapy regimen for CLL.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, Phase 2, single arm, open-label study of oral selinexor monotherapy in patients
      with Richter's transformation, arising in the setting of prior CLL, documented by
      histologically confirmed lymphoma, including diffuse large B-cell (DLBCL) and immunoblastic
      variants. Eligible patients must have had at least one prior regimen for CLL. Approximately
      50 patients are anticipated to be treated in this study. Eligible patients following
      screening will receive selinexor orally twice weekly (e.g., Monday and Wednesday or Tuesday
      and Thursday) at a dose of 60 mg. The selinexor dose may be increased to 80 mg after Cycle 1
      unless clinically contraindicated. Patients may continue in multiple treatment cycles at a
      given dose; there is no maximum treatment duration. Each cycle is 28 days. Dose adjustments
      will be made as appropriate by the investigator.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to enrollment challenges in this rare disease. The termination is not a consequence of any
    safety concern.
  </why_stopped>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>12 weeks</time_frame>
    <description>Overall Response Rate (ORR) (as defined by the IWG Criteria)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Richter's Transformation</condition>
  <arm_group>
    <arm_group_label>selinexor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>orally twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>selinexor</intervention_name>
    <description>60 mg, may be increased to 80 mg after Cycle 1</description>
    <arm_group_label>selinexor</arm_group_label>
    <other_name>KPT-330</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Richter's transformation, arising in the setting of prior CLL, documented by
             histologically confirmed lymphoma, including large B-cell and immunoblastic variants.

          -  All patients must have received at least one prior regimen for CLL, including
             cytotoxic chemotherapy, anti-CD20 monoclonal antibodies, a BTK inhibitor, or a PI3K
             inhibitor. Patients may have received high dose chemotherapy/autologous stem cell
             transplant (HDT/ASCT) or allogeneic hematopoietic stem cell transplant (allo SCT).

          -  One or more measurable (&gt; 1.5 cm in longest dimension) disease sites on CT (preferably
             PET/CT) or, if CT is contraindicated, MRI (preferably PET/MRI) scans.

          -  Objective documented evidence of disease progression at study entry

          -  ECOG status of ≤ 2

        Exclusion Criteria:

          -  Radiation, chemotherapy, or immunotherapy or any other anticancer therapy ≤ 2 weeks
             prior to Cycle 1 Day 1, except ibrutinib which may be continued until one day prior to
             initiation of selinexor; radio-immunotherapy 4 weeks prior to Cycle 1 Day 1. Patients
             must have recovered to Grade ≤ 1 from clinically significant adverse effects.

          -  Prolymphocytic transformation

          -  Less than 1 month since completion of autologous stem cell transplantation or less
             than 3 months since completion of allogeneic stem cell transplantation

          -  Major surgery within 4 weeks of C1D1

          -  Impairment of GI function or GI disease that could interfere with the absorption of
             selinexor, including obstructed GI tract and uncontrolled vomiting or diarrhea.

          -  Inability or unwillingness to take supportive medications including a centrally acting
             appetite stimulant (e.g., mirtazapine or olanzapine) and a peripherally acting
             appetite stimulant (e.g., low dose glucocorticoids or megesterol acetate).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Kauffman, MD, Ph.D</last_name>
    <role>Study Director</role>
    <affiliation>Karyopharm Therapeutics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California-Los Angeles</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute/University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ulm</name>
      <address>
        <city>Ulm</city>
        <state>Baden-Württemberg</state>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Cologne</name>
      <address>
        <city>Koeln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Malopolskie Centrum Medyczne</name>
      <address>
        <city>Kraków</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Copernicus Memorial Hospital, Department of Hematology</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maria Skłodowska-Curie Institue of Oncology</name>
      <address>
        <city>Warszawa</city>
        <zip>02-034</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Navarra, Pamplona</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Català d'Oncologia Av.</name>
      <address>
        <city>Barcelona</city>
        <zip>08010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Vall Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital: Cancer and Haematology Centre</name>
      <address>
        <city>Oxford</city>
        <zip>OX3 8JL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Italy</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2014</study_first_submitted>
  <study_first_submitted_qc>May 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 15, 2014</study_first_posted>
  <last_update_submitted>March 31, 2018</last_update_submitted>
  <last_update_submitted_qc>March 31, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Richter's Transformation</keyword>
  <keyword>Richter's Syndrome</keyword>
  <keyword>Karyopharm</keyword>
  <keyword>selinexor</keyword>
  <keyword>KPT-330</keyword>
  <keyword>SIRRT</keyword>
  <keyword>CLL</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

